Início › Câncer de Pulmão de Não Pequenas Células › Dakota do Sul › Sioux Falls
Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Sioux Falls, SD
19 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Sioux Falls e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecrutandoFase 3
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecrutandoFase 1
- Avera Medical Group, Sioux Falls
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
RecrutandoFase 2
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
RecrutandoFase 3
- Sanford Cancer Center ( Site 3266), Sioux Falls
- Avera Cancer Institute ( Site 3209), Sioux Falls
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecrutandoFase 3
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RecrutandoFase 3
- Avera Cancer Institute, Sioux Falls
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RecrutandoFase 3
- Sanford Cancer Center ( Site 0053), Sioux Falls
- Avera Cancer Institute- Research ( Site 0090), Sioux Falls
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RecrutandoFase 3
- Avera Cancer Institute- Research, Sioux Falls
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RecrutandoFase 3
- Research Site, Sioux Falls
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RecrutandoFase 3
- Research Site, Sioux Falls
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RecrutandoFase 2/3
- Avera Cancer Institute, Sioux Falls
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
RecrutandoEstudo observacional
- Sanford Cancer Center ( Site 0038), Sioux Falls
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
RecrutandoFase 1/2
- Sanford Cancer Center ( Site 0038), Sioux Falls
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
RecrutandoFase 2
- Sanford Cancer Center ( Site 0038), Sioux Falls
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecrutandoFase 1
- Sanford Cancer Center, Sioux Falls
- Sanford USD Medical Center, Sioux Falls
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RecrutandoFase 2
- Sanford Cancer Center, Sioux Falls
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecrutandoFase 2
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecrutandoFase 2/3
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecrutandoFase 2
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
Ensaios de Câncer de Pulmão de Não Pequenas Células em outras cidades
- Houston, TX145 estudos
- New York City, NY121 estudos
- Arlington, VA104 estudos
- Nashville, TN97 estudos
- Boston, MA90 estudos
- Los Angeles, CA87 estudos
- St. Louis, MO73 estudos
- Chicago, IL61 estudos
- Baltimore, MD60 estudos
- San Antonio, TX59 estudos
- Columbus, OH57 estudos
- Washington, DC55 estudos
Outros estudos em Sioux Falls
- Câncer de Mama18 estudos
- Câncer de Ovário16 estudos
- Câncer de Pulmão14 estudos
- Câncer (todos os tipos)13 estudos
- Câncer Endometrial11 estudos
- Câncer Metastático10 estudos
- Câncer Colorretal9 estudos
- Carcinoma de Células Escamosas de Cabeça e Pescoço9 estudos
- Insuficiência Cardíaca7 estudos
- Câncer de Cólon7 estudos
- Câncer de Mama Triplo-Negativo7 estudos
- Câncer de Próstata7 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.